344 related articles for article (PubMed ID: 21127352)
1. Metabolomics in toxicology: preclinical and clinical applications.
Robertson DG; Watkins PB; Reily MD
Toxicol Sci; 2011 Mar; 120 Suppl 1():S146-70. PubMed ID: 21127352
[No Abstract] [Full Text] [Related]
2. Metabolic profiling as a tool for understanding mechanisms of toxicity.
Clarke CJ; Haselden JN
Toxicol Pathol; 2008 Jan; 36(1):140-7. PubMed ID: 18337232
[TBL] [Abstract][Full Text] [Related]
3. Metabolomics and its potential in drug development.
Beyoğlu D; Idle JR
Biochem Pharmacol; 2013 Jan; 85(1):12-20. PubMed ID: 22935449
[TBL] [Abstract][Full Text] [Related]
4. Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?
Kroll F; Dreger M
Future Med Chem; 2010 Nov; 2(11):1613-7. PubMed ID: 21428831
[No Abstract] [Full Text] [Related]
5. Metabolic and kinetic aspects of toxicological studies. 19 May 1987, Paris, France.
Xenobiotica; 1988 Jan; 18 Suppl 1():1-96. PubMed ID: 3344587
[No Abstract] [Full Text] [Related]
6. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
Jacobs A
Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment of drug residues.
Jackson BA
J Am Vet Med Assoc; 1980 May; 176(10 Spec No):1141-4. PubMed ID: 6894293
[TBL] [Abstract][Full Text] [Related]
8. The potential of metabolomic approaches for investigating mode(s) of action of xenobiotics: case study with carbon tetrachloride.
Vulimiri SV; Berger A; Sonawane B
Mutat Res; 2011 Jun; 722(2):147-53. PubMed ID: 20188855
[TBL] [Abstract][Full Text] [Related]
9. Metabonomic modeling of drug toxicity.
Keun HC
Pharmacol Ther; 2006 Jan; 109(1-2):92-106. PubMed ID: 16051371
[TBL] [Abstract][Full Text] [Related]
10. In silico methods for early toxicity assessment.
Merlot C
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):80-5. PubMed ID: 18175270
[TBL] [Abstract][Full Text] [Related]
11. Metabonomics in the preclinical and environmental toxicity field.
Colet JM
Drug Discov Today Technol; 2015 Jun; 13():3-10. PubMed ID: 26190677
[TBL] [Abstract][Full Text] [Related]
12. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: A review.
Roux A; Lison D; Junot C; Heilier JF
Clin Biochem; 2011 Jan; 44(1):119-35. PubMed ID: 20800591
[TBL] [Abstract][Full Text] [Related]
13. Evaluations of organ system development in juvenile toxicology testing.
Robinson K
Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
[TBL] [Abstract][Full Text] [Related]
14. [Animal model and drug activity (proceedings)].
Rico AG
Ann Biol Clin (Paris); 1978; 36(3):214-7. PubMed ID: 101102
[No Abstract] [Full Text] [Related]
15. Preclinical assessment of cardiac toxicity.
Kettenhofen R; Bohlen H
Drug Discov Today; 2008 Aug; 13(15-16):702-7. PubMed ID: 18602016
[TBL] [Abstract][Full Text] [Related]
16. Application of pharmacokinetic principles in the extrapolation of animal data to humans.
Gillette JR
Clin Toxicol; 1976; 9(5):709-22. PubMed ID: 1000904
[No Abstract] [Full Text] [Related]
17. Biopharmaceutical studies, a key to better toxicology.
Zbinden G
Xenobiotica; 1988 Jan; 18 Suppl 1():9-14. PubMed ID: 3344592
[No Abstract] [Full Text] [Related]
18. A search to predict potential for drug-induced cardiovascular toxicity.
Hamlin RL
Toxicol Pathol; 2006; 34(1):75-80. PubMed ID: 16507547
[TBL] [Abstract][Full Text] [Related]
19. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
Palucki M; Higgins JD; Kwong E; Templeton AC
J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
[No Abstract] [Full Text] [Related]
20. [What do we know about the drug metabolism?].
Pelkonen O; Raunio H
Duodecim; 1998; 114(10):971-7. PubMed ID: 11524785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
